These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
251 related articles for article (PubMed ID: 19148677)
1. Clinical practice: pulmonary hypertension in children. De Wolf D Eur J Pediatr; 2009 May; 168(5):515-22. PubMed ID: 19148677 [TBL] [Abstract][Full Text] [Related]
2. [Treatment with sildenafil, bosentan, or both in children and young people with idiopathic pulmonary arterial hypertension and Eisenmenger's syndrome]. Raposo-Sonnenfeld I; Otero-González I; Blanco-Aparicio M; Ferrer-Barba A; Medrano-López C Rev Esp Cardiol; 2007 Apr; 60(4):366-72. PubMed ID: 17521545 [TBL] [Abstract][Full Text] [Related]
3. Better off blue: BMPR-2 mutation, arteriovenous malformation, and pulmonary arterial hypertension. Soon E; Southwood M; Sheares K; Pepke-Zaba J; Morrell NW Am J Respir Crit Care Med; 2014 Jun; 189(11):1435-6. PubMed ID: 24881940 [No Abstract] [Full Text] [Related]
4. Treatment of pulmonary hypertension in children with chronic lung disease with newer oral therapies. Krishnan U; Krishnan S; Gewitz M Pediatr Cardiol; 2008 Nov; 29(6):1082-6. PubMed ID: 18594787 [TBL] [Abstract][Full Text] [Related]
5. An evidence-based approach to the management of pulmonary arterial hypertension. Archer SL; Michelakis ED Curr Opin Cardiol; 2006 Jul; 21(4):385-92. PubMed ID: 16755209 [TBL] [Abstract][Full Text] [Related]
7. Pulmonary arterial hypertension associated with congenital heart disease. D'Alto M; Mahadevan VS Eur Respir Rev; 2012 Dec; 21(126):328-37. PubMed ID: 23204121 [TBL] [Abstract][Full Text] [Related]
8. Pulmonary arterial hypertension: combination therapy in the modern management era. Sitbon O Eur Respir Rev; 2010 Dec; 19(118):348-9. PubMed ID: 21119195 [No Abstract] [Full Text] [Related]
9. Bosentan for the treatment of portopulmonary hypertension. Tempe DK; Datt V; Datta D Ann Card Anaesth; 2008; 11(2):139-40; author reply 140. PubMed ID: 18603763 [No Abstract] [Full Text] [Related]
10. [Bosentan and chronic thromboembolic pulmonary hypertension]. Tomás C; Callejas-Rubio JL; Ríos-Fernández R; Ortego-Centeno N Med Clin (Barc); 2007 Nov; 129(16):639. PubMed ID: 18001681 [No Abstract] [Full Text] [Related]
11. Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation. Chen YF; Jowett S; Barton P; Malottki K; Hyde C; Gibbs JS; Pepke-Zaba J; Fry-Smith A; Roberts J; Moore D Health Technol Assess; 2009 Oct; 13(49):1-320. PubMed ID: 19863849 [TBL] [Abstract][Full Text] [Related]
12. Combination drug therapy in the management of pulmonary arterial hypertension. Kayser SR Prog Cardiovasc Nurs; 2005; 20(4):177-82. PubMed ID: 16276142 [No Abstract] [Full Text] [Related]
13. The efficacy and safety of sildenafil in patients with pulmonary arterial hypertension associated with the different types of congenital heart disease. Zeng WJ; Lu XL; Xiong CM; Shan GL; Liu ZH; Ni XH; Gu Q; Zhao ZH; Li JJ; He JG; Clin Cardiol; 2011 Aug; 34(8):513-8. PubMed ID: 21678455 [TBL] [Abstract][Full Text] [Related]
14. Treatment of severe pulmonary hypertension secondary to scleroderma: a three-drug approach. Catapano-Minotti G; Corsonello A; Guadalupi G; Spani R; Antonelli-Incalzi R Intern Med; 2008; 47(6):511-3. PubMed ID: 18344637 [TBL] [Abstract][Full Text] [Related]
15. The management of Eisenmenger syndrome in the modern treatment era: a case report. Gatzoulis MA Eur Respir Rev; 2011 Dec; 20(122):293-6. PubMed ID: 22130823 [No Abstract] [Full Text] [Related]
16. Safety and tolerability of targeted therapies for pulmonary hypertension in children. Roldan T; Deiros L; Romero JA; Gutierrez-Larraya F; Herrero A; Del Cerro MJ Pediatr Cardiol; 2014 Mar; 35(3):490-8. PubMed ID: 24141893 [TBL] [Abstract][Full Text] [Related]